Cordis DX® is a series of clinically verified, highly sensitive and specific multi-gene tests that analyze the genes associated with inherited cardiovascular diseases such as:
Why Cordis DX® molecular tests are important
Cordis DX® series genetic tests analyze a total of up to 257 genes and help in:
Diagnosis: Confirms the clinical diagnosis in a reliable and fast way and reduces the need for more invasive procedures. Accurate diagnosis of inherited cardiovascular diseases is now possible with the use of genetic analysis, which minimizes dilemmas regarding the management and prognosis of the disease and assists the physician in estimating the time for surgery. The contribution of the test to the diagnosis of hereditary arrhythmogenic diseases (channelopathies or canalopathies) that pose a high risk of sudden death in the soil of a structurally normal heart (eg long QT syndrome, Brugada syndrome, etc.) is important.
Prognosis: By knowing exactly the gene mutations that are responsible for a patient's disease, we can predict its progression, taking into account all the factors that concern the specific patient. We can also identify relatives who carry the same mutation and are at increased risk of developing the same disease and be properly managed as appropriate. The test's contribution is particularly important in families that carry genes associated with sudden death.
Management: The proper management of the patient and his family is based on the correct diagnosis and prognosis of the disease, so that the doctor is oriented towards the most appropriate treatment and patient management. Informs about the avoidance of certain medications and guides lifestyle modifications to avoid causing heart attacks as much as possible. Assists in the decision for early surgery and placement of an implantable cardiac defibrillator or pacemaker. Identifies appropriate control intervals and possible interventions for at-risk family members
For the analysis we need 2 vials of blood with EDTA
To see indicative panels please click here.
CordisDX® genetic analysis offers the physician maximum differential diagnosis, with high rates of sensitivity and specificity, saving valuable time and cost per patient case.
»Recommended by the European Society of Cardiology and the European Respiratory Society for the diagnosis and management of pulmonary hypertension
»Recommended by the Heart Rhythm Society (HRS) and European Heart Rhythm Association (EHRA) for the diagnosis and management of channelopathies.
»Recommended by the American Association of Cardiologists for the diagnosis and management of arrhythmias.
»Recommended by the Heart Failure Society of America and the European Society of Cardiology for the diagnosis and management of cardiomyopathy.